Overview

A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer

Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Eli Lilly and Company
Treatments:
Carboplatin
Pemetrexed